In vitro and in vivo evaluation of a once-weekly formulation of an antidiabetic peptide drug exenatide in an injectable thermogel.

Lin Yu,Kun Li,Xiaojun Liu,Chang Chen,Yongchu Bao,Tianyuan Ci,Qinghua Chen,Jiandong Ding
DOI: https://doi.org/10.1002/jps.23735
IF: 3.8
2013-01-01
Journal of Pharmaceutical Sciences
Abstract:An injectable thermogel composed of poly(lactic acid-co-glycolic acid)-poly(ethylene glycol)-poly(lactic acid-co-glycolic acid) (PLGA–PEG–PLGA) triblock copolymers was evaluated as the matrix of a long-acting drug delivery system of exenatide (EXT), an antidiabetic peptide. The optimal gel formulation containing 2mg/mL EXT and three pharmaceutical excipients (1.25 wt % zinc acetate, 5 wt % PEG200, and 5 wt % sucrose) was injected subcutaneously, and its pharmacokinetics was investigated. Both in vitro and in vivo release profiles exhibited a sustained release of EXT over 1 week. After a subcutaneous injection of the EXT formulation into db/db mice, the blood glucose level was maintained in a normal range up to 7 days and meanwhile the growth of body weight was suppressed. The in vivo results were consistent with the in vitro EXT-release profile. Moreover, twice injections of the gel formulation resulted in the higher blood insulin level and lower plasma concentration of glycosylated hemoglobin compared with twice-daily injections of an EXT solution for 18 days. Histological observations manifested the protection of islet due to administration of the gel formulation. Therefore, the PLGA–PEG–PLGA thermogel provided an excellent candidate for a once-weekly delivery system of EXT, and the optimal EXT formulation not only afforded therapeutic efficacy but also improved patient compliance.
What problem does this paper attempt to address?